In silico assessment of drug safety in human heart applied to late sodium current blockers

Channels

Volumn 7, Issue 4, 2013, Pages 249-262

  Trenor, Beatriz ^a   Gomis Tena, Julio ^a   Cardona, Karen ^a   Romero, Lucia ^a   Rajamani, Sridharan ^b   Belardinelli, Luiz ^b   Giles, Wayne R ^c   Saiz, Javier ^a  

^a UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^b Gilead Sciences   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Anti arrhythmic; Drug safety; Late sodium current; Multi channel block; Reverse rate dependence; Transmural dispersion of repolarization

Indexed keywords

ANTIARRHYTHMIC AGENT; DELAYED RECTIFIER POTASSIUM CHANNEL; GS 967; RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; POTASSIUM CHANNEL; SODIUM;

ARTICLE; COMPUTER MODEL; DRUG SAFETY; HEART; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; QT INTERVAL; SODIUM CURRENT; STEADY STATE; TRIANGULATION; ACTION POTENTIAL; COMPUTER SIMULATION; DRUG EFFECTS; ELECTROPHYSIOLOGY; HEART VENTRICLE; HEART VENTRICLE FUNCTION; HUMAN; KINETICS; METABOLISM; RISK; SAFETY;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; COMPUTER SIMULATION; ELECTROPHYSIOLOGICAL PROCESSES; HEART VENTRICLES; HUMANS; KINETICS; POTASSIUM CHANNELS; RISK; SAFETY; SODIUM; SODIUM CHANNEL BLOCKERS; VENTRICULAR FUNCTION;

EID: 84885627215     PISSN: 19336950     EISSN: 19336969     Source Type: Journal    
DOI: 10.4161/chan.24905     Document Type: Article

References (80)

1. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail 2007; 9:219-27; PMID:17067855; http://dx.doi.org/10.1016/j.ejheart.2006.08.007
2. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current." Pharmacol Ther 2008; 119:326-39; PMID:18662720; http://dx.doi.org/10.1016/j.pharmthera.2008.06.001
3. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 2006; 318:214- 22; PMID:16565163; http://dx.doi.org/10.1124/jpet.106.101832
4. Milberg P, Pott C, Fink M, Frommeyer G, Matsuda T, Baba A, et al. Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3. Heart Rhythm 2008; 5:1444-52; PMID:18929333; http://dx.doi.org/10.1016/j.hrthm.2008.06.017
5. Jia S, Lian J, Guo D, Xue X, Patel C, Yang L, et al. Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade. Br J Pharmacol 2011; 164:308-16; PMID:21182492; http://dx.doi.org/10.1111/j.1476-5381.2010.01181.x
6. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006; 17(Suppl 1):S169-77; PMID:16686675; http://dx.doi.org/10. 1111/j.1540-8167.2006.00401.x
7. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004; 310:599- 605; PMID:15031300; http://dx.doi.org/10.1124/jpet.104.066100
8. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 2008; 19:1289-93; PMID:18662191; http://dx.doi.org/10.1111/j.1540-8167.2008.01246.x
9. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004; 44:192-9; PMID:15243300; http://dx.doi.org/10.1097/00005344-200408000-00008
10. Belardinelli L, Liu G, Smith-Maxwell C, Wang WQ, El-Bizri N, Hirakawa R, et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther 2013; 344:23-32; PMID:23010360; http://dx.doi.org/10.1124/jpet.112.198887
11. Bányász T, Koncz R, Fülöp L, Szentandrássy N, Magyar J, Nánási PP. Profile of I(Ks) during the action potential questions the therapeutic value of I(Ks) blockade. Curr Med Chem 2004; 11:45-60; PMID:14754425; http://dx.doi.org/10.2174/0929867043456304
12. Carro J, Rodriguez JF, Laguna P, Pueyo E. A human ventricular cell model for investigation of cardiac arrhythmias under hyperkalaemic conditions. Philos Transact A Math Phys. Eng Sci 1954; 2011:4205-32
13. Fink M, Giles WR, Noble D. Contributions of inwardly rectifying K+ currents to repolarization assessed using mathematical models of human ventricular myocytes. Philos Transact A Math Phys. Eng Sci 1842; 2006:1207-22
14. Hopenfeld B. A mathematical analysis of the action potential plateau duration of a human ventricular myocyte. J Theor Biol 2006; 240:311-22; PMID:16303142; http://dx.doi.org/10.1016/j.jtbi.2005.09.021
15. Maleckar MM, Greenstein JL, Giles WR, Trayanova NA. Electrotonic coupling between human atrial myocytes and fibroblasts alters myocyte excitability and repolarization. Biophys J 2009; 97:2179-90; PMID:19843450; http://dx.doi.org/10. 1016/j.bpj.2009.07.054
16. Nygren A, Fiset C, Firek L, Clark JW, Lindblad DS, Clark RB, et al. Mathematical model of an adult human atrial cell: the role of K+ currents in repolarization. Circ Res 1998; 82:63-81; PMID:9440706; http://dx.doi.org/10. 1161/01.RES.82.1.63
17. Viswanathan PC, Rudy Y. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc Res 1999; 42:530-42; PMID:10533588; http://dx.doi.org/10.1016/S0008- 6363(99)00035-8
18. Wu R, Patwardhan A. Effects of rapid and slow potassium repolarization currents and calcium dynamics on hysteresis in restitution of action potential duration. J Electrocardiol 2007; 40:188-99; PMID:16895773; http://dx.doi.org/10. 1016/j.jelectrocard.2006.01.001
19. Zaniboni M. 3D current-voltage-time surfaces unveil critical repolarization differences underlying similar cardiac action potentials: A model study. Math Biosci 2011; 233:98-110; PMID:21781977; http://dx.doi.org/10.1016/ j.mbs.2011.06.008
20. Zaniboni M. Late phase of repolarization is autoregenerative and scales linearly with action potential duration in mammals ventricular myocytes: a model study. IEEE Trans Biomed Eng 2012; 59:226-33; PMID:21990326; http://dx.doi.org/10.1109/TBME.2011.2170987
21. Zaniboni M, Riva I, Cacciani F, Groppi M. How different two almost identical action potentials can be: a model study on cardiac repolarization. Math Biosci 2010; 228:56-70; PMID:20801131; http://dx.doi.org/10.1016/j.mbs. 2010.08.007
22. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003; 24:619-25; PMID:14654302; http://dx.doi.org/10.1016/j.tips.2003.10.002
23. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005; 2:758-72; PMID:15992736; http://dx.doi.org/10.1016/j.hrthm.2005.03.023
24. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001; 103:2004- 13; PMID:11306531; http://dx.doi.org/10.1161/01.CIR.103.15.2004
25. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, et al. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res 2011; 91:53-61; PMID:21300721; http://dx.doi.org/10.1093/cvr/cvr044
26. Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M. A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J Chem Inf Model 2011; 51:483-92; PMID:21250697; http://dx.doi.org/10.1021/ci100423z
27. Suzuki S, Murakami S, Tsujimae K, Findlay I, Kurachi Y. In silico risk assessment for drug-induction of cardiac arrhythmia. Prog Biophys Mol Biol 2008; 98:52-60; PMID:18635251; http://dx.doi.org/10.1016/j.pbiomolbio.2008.05.003
28. Mirams GR, Davies MR, Cui Y, Kohl P, Noble D. Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing. Br J Pharmacol 2012; 167:932-45; PMID:22568589; http://dx.doi.org/10.1111/j.1476-5381.2012. 02020.x
29. Sarkar AX, Sobie EA. Quantification of repolarization reserve to understand interpatient variability in the response to proarrhythmic drugs: a computational analysis. Heart Rhythm 2011; 8:1749- 55; PMID:21699863; http://dx.doi.org/10.1016/j.hrthm.2011.05.023
30. Chang CC, Acharfi S, Wu MH, Chiang FT, Wang JK, Sung TC, et al. A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardia. Cardiovasc Res 2004; 64:268-78; PMID:15485686; http://dx.doi.org/10.1016/j.cardiores.2004.07.007
31. Weirich J, Antoni H. Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs. Basic Res Cardiol 1998; 93(Suppl 1):125-32; PMID:9833140; http://dx.doi.org/10.1007/s003950050236
32. O'Hara T, Virág L, Varró A, Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol 2011; 7:e1002061; PMID:21637795; http://dx.doi.org/10.1371/journal.pcbi.1002061
33. Wu L, Ma J, Li H, Wang C, Grandi E, Zhang P, et al. Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation 2011; 123:1713- 20; PMID:21482963; http://dx.doi.org/10.1161/CIRCULATIONAHA.110.000661
34. Bányász T, Bárándi L, Harmati G, Virág L, Szentandrássy N, Márton I, et al. Mechanism of reverse rate-dependent action of cardioactive agents. Curr Med Chem 2011; 18:3597-606; PMID:21774765; http://dx.doi.org/10.2174/092986711796642355
35. Noble D, Tsien RW. The repolarization process of heart cells. In: DeMello WC, ed. Electrical Phenomena in the Heart. New York: Academic Press, 1972:133-161.
36. Fink M, Noble D, Virag L, Varro A, Giles WR. Contributions of HERG K+ current to repolarization of the human ventricular action potential. Prog Biophys Mol Biol 2008; 96:357-76; PMID:17919688; http://dx.doi.org/10.1016/j. pbiomolbio.2007.07.011
37. Goineau S, Castagné V, Guillaume P, Froget G. The comparative sensitivity of three in vitro safety pharmacology models for the detection of lidocaineinduced cardiac effects. J Pharmacol Toxicol Methods 2012; 66:52-8; PMID:22691624; http://dx.doi.org/10.1016/j.vascn.2012.06.001
38. Wu L, Guo D, Li H, Hackett J, Yan GX, Jiao Z, et al. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm 2008; 5:1726-34; PMID:19084812; http://dx.doi.org/10.1016/j.hrthm. 2008.09.008
39. Diness JG, Hansen RS, Nissen JD, Jespersen T, Grunnet M. Antiarrhythmic effect of IKr activation in a cellular model of LQT3. Heart Rhythm 2009; 6:100-6; PMID:19121808; http://dx.doi.org/10.1016/j.hrthm.2008.10.020
40. Laursen M, Olesen SP, Grunnet M, Mow T, Jespersen T. Characterization of cardiac repolarization in the Göttingen minipig. J Pharmacol Toxicol Methods 2011; 63:186-95; PMID:20951813; http://dx.doi.org/10.1016/j.vascn.2010. 10.001
41. Hondeghem LM. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 2006; 17:337-40; PMID:16643415; http://dx.doi.org/10.1111/j.1540- 8167.2006.00347.x
42. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81:686-90; PMID:2153477; http://dx.doi.org/10. 1161/01.CIR.81.2.686
43. Bril A, Forest MC, Cheval B, Faivre JF. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL- 32872 and azimilide. Cardiovasc Res 1998; 37:130-40; PMID:9539867; http://dx.doi.org/10. 1016/S0008-6363(97)00216-2
44. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993; 72:75-83; PMID:8417848; http://dx.doi.org/10.1161/01.RES.72.1.75
45. O'Hara T, Rudy Y. Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. Am J Physiol Heart Circ Physiol 2012; 302:H1023-30; PMID:22159993; http://dx.doi.org/10.1152/ajpheart. 00785.2011
46. Stengl M, Volders PG, Thomsen MB, Spätjens RL, Sipido KR, Vos MA. Accumulation of slowly activating delayed rectifier potassium current (IKs) in canine ventricular myocytes. J Physiol 2003; 551:777-86; PMID:12819301; http://dx.doi.org/10.1113/jphysiol. 2003.044040
47. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54:188-202; PMID:12207642; http://dx.doi.org/10.1046/j.1365-125. 2002.01627.x
48. Nuyens D, Stengl M, Dugarmaa S, Rossenbacker T, Compernolle V, Rudy Y, et al. Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med 2001; 7:1021-7; PMID:11533705; http://dx.doi.org/10.1038/nm0901-1021
49. Gautier M, Zhang H, Fearon IM. Peroxynitrite formation mediates LPC-induced augmentation of cardiac late sodium currents. J Mol Cell Cardiol 2008; 44:241- 51; PMID:17961592; http://dx.doi.org/10.1016/j.yjmcc.2007.09.007
50. Fearon IM, Brown ST. Acute and chronic hypoxic regulation of recombinant hNa(v)1.5 alpha subunits. Biochem Biophys Res Commun 2004; 324:1289- 95; PMID:15504354; http://dx.doi.org/10.1016/j.bbrc.2004.09.188
51. Ward CA, Giles WR. Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol 1997; 500:631-42; PMID:9161981
52. Saint DA. The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol153:1133-42; PMID:18071303; http://dx.doi.org/10.1038/sj. bjp.0707492
53. Zygmunt AC, Eddlestone GT, Thomas GP, Nesterenko VV, Antzelevitch C. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol 2001; 281:H689-97; PMID:11454573
54. Trenor B, Cardona K, Gomez JF, Rajamani S, Ferrero JM Jr., Belardinelli L, et al. Simulation and mechanistic investigation of the arrhythmogenic role of the late sodium current in human heart failure. PLoS One 2012; 7:e32659; PMID:22427860; http://dx.doi.org/10.1371/journal.pone.0032659
55. Wasserstrom JA, Salata JJ. Basis for tetrodotoxin and lidocaine effects on action potentials in dog ventricular myocytes. Am J Physiol 1988; 254:H1157-66; PMID:2454585
56. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 2004; 43:369-79; PMID:15076220; http://dx.doi.org/10.1097/00005344-200403000-00007
57. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110:904-10; PMID:15302796; http://dx.doi.org/10.1161/01. CIR.0000139333.83620.5D
58. Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 2006; 92(Suppl 4):iv1-5; PMID:16775091; http://dx.doi.org/10.1136/hrt.2005.078782
59. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116:1647-52; PMID:17804441; http://dx.doi.org/10.1161/ CIRCULATIONAHA.107.724880
60. Hoefen R, Reumann M, Goldenberg I, Moss AJ, O-Uchi J, Gu Y, et al. In silico cardiac risk assessment in patients with long QT syndrome: type 1: clinical predictability of cardiac models. J Am Coll Cardiol 2012; 60:2182-91; PMID:23153844; http://dx.doi.org/10.1016/j.jacc.2012.07.053
61. Silva JR, Pan H, Wu D, Nekouzadeh A, Decker KF, Cui J, et al. A multiscale model linking ionchannel molecular dynamics and electrostatics to the cardiac action potential. Proc Natl Acad Sci U S A 2009; 106:11102-6; PMID:19549851; http://dx.doi.org/10.1073/pnas.0904505106
62. Starmer CF, Nesterenko VV, Undrovinas AI, Grant AO, Rosenshtraukh LV. Lidocaine blockade of continuously and transiently accessible sites in cardiac sodium channels. J Mol Cell Cardiol 1991; 23(Suppl 1):73-83; PMID:1645414; http://dx.doi.org/10.1016/0022-2828(91)90026-I
63. Rudy Y, Silva Jr. Computational biology in the study of cardiac ion channels and cell electrophysiology. Q Rev Biophys 2006; 39:57-116; PMID:16848931; http://dx.doi.org/10.1017/S0033583506004227
64. Clancy CE, Zhu ZI, Rudy Y. Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol 2007; 292:H66- 75; PMID:16997895; http://dx.doi.org/10.1152/ajpheart.00312.2006
65. Zygmunt AC, Nesterenko VV, Rajamani S, Hu D, Barajas-Martinez H, Belardinelli L, et al. Mechanisms of atrial-selective block of Na+ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol 2011; 301:H1606- 14; PMID:21821778; http://dx.doi.org/10. 1152/ajpheart.00242.2011
66. Nesterenko VV, Zygmunt AC, Rajamani S, Belardinelli L, Antzelevitch C. Mechanisms of atrial-selective block of Na+ channels by ranolazine: II. Insights from a mathematical model. Am J Physiol Heart Circ Physiol 2011; 301:H1615-24; PMID:21821780; http://dx.doi.org/10.1152/ajpheart.00243.2011
67. Zemzemi N, Bernabeu MO, Saiz J, Cooper J, Pathmanathan P, Mirams GR, et al. Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentials. Br J Pharmacol 2013; 168:718-33; PMID:22946617; http://dx.doi.org/10.1111/j.1476-5381.2012.02200.x
68. Hille B. Ionic Channels of Excitable Membranes. 2nd ed. Sunderland, MA: Sinauer Associates, 1992.
69. Rajamani S, Shryock JC, Belardinelli L. Rapid kinetic interactions of ranolazine with HERG K+ current. J Cardiovasc Pharmacol 2008; 51:581-9; PMID:18520952; http://dx.doi.org/10.1097/FJC.0b013e3181799690
70. Rajamani S, El-Bizri N, Shryock JC, Makielski JC, Belardinelli L. Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm 2009; 6:1625-31; PMID:19879541; http://dx.doi.org/10.1016/j.hrthm.2009.07.042
71. Bassingthwaighte J, Hunter P, Noble D. The Cardiac Physiome: perspectives for the future. Exp Physiol 2009; 94:597-605; PMID:19098089; http://dx.doi.org/10.1113/expphysiol.2008.044099
72. Quinn TA, Granite S, Allessie MA, Antzelevitch C, Bollensdorff C, Bub G, et al. Minimum Information about a Cardiac Electrophysiology Experiment (MICEE): standardised reporting for model reproducibility, interoperability, and data sharing. Prog Biophys Mol Biol 2011; 107:4-10; PMID:21745496; http://dx.doi.org/10.1016/j.pbiomolbio.2011.07.001
73. Glukhov AV, Fedorov VV, Lou Q, Ravikumar VK, Kalish PW, Schuessler RB, et al. Transmural dispersion of repolarization in failing and nonfailing human ventricle. Circ Res 2010; 106:981-91; PMID:20093630; http://dx.doi.org/10.1161/ CIRCRESAHA.109.204891
74. Maltsev VA, Undrovinas AI. A multi-modal composition of the late Na+ current in human ventricular cardiomyocytes. Cardiovasc Res 2006; 69:116-27; PMID:16223473; http://dx.doi.org/10.1016/j.cardiores. 2005.08.015
75. Li GR, Feng J, Yue L, Carrier M. Transmural heterogeneity of action potentials and Ito1 in myocytes isolated from the human right ventricle. Am J Physiol 1998; 275:H369-77; PMID:9683422
76. Drouin E, Charpentier F, Gauthier C, Laurent K, Le Marec H. Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: evidence for presence of M cells. J Am Coll Cardiol 1995; 26:185-92; PMID:7797750; http://dx.doi.org/10.1016/0735-1097(95)00167-X
77. Berecki G, Zegers JG, Bhuiyan ZA, Verkerk AO, Wilders R, van Ginneken AC. Long-QT syndromerelated sodium channel mutations probed by the dynamic action potential clamp technique. J Physiol 2006; 570:237-50; PMID:16254012
78. Maltsev VA, Silverman N, Sabbah HN, Undrovinas AI. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail 2007; 9:219-27; PMID:17067855; http://dx.doi.org/10.1016/j.ejheart.2006.08.007
79. Valdivia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR, et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 2005; 38:475-83; PMID:15733907; http://dx.doi.org/10.1016/j. yjmcc.2004.12.012
80. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006; 92(Suppl 4):iv6- 14; PMID:16775092; http://dx.doi.org/10.1136/hrt.2005.078790